NCT02934256 - Icotinib Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 31, 2016

Primary Completion Date

July 31, 2018

Study Completion Date

July 31, 2018

Conditions

Vestibular SchwannomaNeurofibromatosis Type 2

Interventions

DRUG

Icotinib

Method of drug administration:oral; Dosage: 125mg/m3/d; Course of treatment: 3 months;Total four treatment courses.

Trial Locations (2)

Beijing Tiantan Hospital Affiliated to Capital Medical University, Beijing